SCHEMBL1984293

SCHEMBL1984293

CCc1c(C#N)ccc(N)c1I

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.34
MAPT P10636 2/20 0.34
POLB P06746 1/20 0.34
USP7 Q93009 2/20 0.34
KDM4E B2RXH2 3/20 0.33
USP2 O75604 1/20 0.33
MEN1 O00255 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
ALOX12 P18054 1/20 0.33
BRCA1 P38398 1/20 0.33
KMT2A Q03164 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
ADRB2 P07550 1/20 0.32
ADRB1 P08588 1/20 0.32
ADRB3 P13945 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21753704 0.82 ALDH1A1 (0.37) ALDH1A1MAPTPOLBUSP7KDM4E
SCHEMBL28571188 0.79 PGR (0.33) ALDH1A1KDM4EHPGDHSD17B10CYP2A6
SCHEMBL1704559 0.76 KDM4E (0.35) ALDH1A1MAPTKDM4EUSP2MEN1
SCHEMBL18299825 0.75 ALDH1A1 (0.36) ALDH1A1MAPTPOLBKDM4EUSP2
SCHEMBL18704482 0.74 AR (0.41) ALDH1A1MAPTPOLBUSP7KDM4E
SCHEMBL12342668 0.70 TRPV4 (0.36) CYP2A6
SCHEMBL2968418 0.70 AR (0.42)
SCHEMBL28574963 0.69 AR (0.36) ALDH1A1KDM4EHPGDHSD17B10CYP2A6
SCHEMBL6137335 0.69 SKP2 (0.43) ALDH1A1MAPTKDM4EUSP2MEN1
SCHEMBL16771350 0.69 TSHR (0.46) ALDH1A1KDM4EHPGDHSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120283297-A1 OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS GLAXO WELLCOME HOUSE (GB) 2012-11-08 US disclosed
EP-2513095-A1 OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS Glaxo Group Limited (GB) 2012-10-24 EP disclosed
WO-2011072488-A1 OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283297-A1 OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS S1PR1, S1PR3, S1PR2 ALDH1A1 2182/4885MAPT 3368/4885POLB 3573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.